Yield of baseline imaging for distant metastases in high-risk primary melanoma

J Surg Oncol. 2022 Jun;125(8):1312-1317. doi: 10.1002/jso.26846. Epub 2022 Mar 9.

Abstract

Background: The yield of baseline imaging in patients presenting with higher risk primary tumours, at least American Joint Committee on Cancer 8th edition stage IIC or III melanoma, is unclear.

Methods: This retrospective study included patients referred to the Victorian Melanoma Service from January 2017 to April 2020, diagnosed with at least stage IIC or stage III melanoma. Patients with a T4b tumour and no sentinel lymph node biopsy were included as 'T4bNX'.

Results: One hundred and sixty-four patients (median age 65 years) with baseline imaging (T4bNX: 19, IIC: 30, IIIA: 21, IIIB: 43, IIIC: 50, IIID: 1) were included. The majority were male (73%), and those with T4bNX melanoma tended to be older (median age 79 years). Distant metastases were detected in 21% (4/19) of T4bNX, 3% (1/30) of stage IIC, 0% (0/21) of stage IIIA, and 6% (6/94) of stages IIIB-D melanoma patients. All stage III patients with distant metastases had palpable lymphadenopathy a presentation. Two patients had brain metastases, both of whom had T4bNX melanoma and synchronous extra-cranial metastases.

Conclusions: Compared to stage IIC, baseline imaging detects higher rates of extra-cranial distant disease in stages IIIB-D and T4bNX melanoma. Intracranial imaging has greater yield in patients with distant extra-cranial disease.

Keywords: PET computed tomography; diagnostic imaging; melanoma; staging; surveillance.

MeSH terms

  • Aged
  • Female
  • Humans
  • Male
  • Melanoma* / pathology
  • Neoplasm Staging
  • Retrospective Studies
  • Sentinel Lymph Node Biopsy
  • Skin Neoplasms* / pathology